ex24-05312022_020511.htm

0001415889-22-005928.txt : 20220531 0001415889-22-005928.hdr.sgml : 20220531 20220531172720 ACCESSION NUMBER: 0001415889-22-005928 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20220526 FILED AS OF DATE: 20220531 DATE AS OF CHANGE: 20220531 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Greenfield Andrew J CENTRAL INDEX KEY: 0001372715 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-09585 FILM NUMBER: 22984840 BUSINESS ADDRESS: BUSINESS PHONE: 978-352-3815 MAIL ADDRESS: STREET 1: 14 HILLSIDE DRIVE CITY: GEORGETOWN STATE: MA ZIP: 01833 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ABIOMED INC CENTRAL INDEX KEY: 0000815094 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 042743260 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 BUSINESS ADDRESS: STREET 1: 22 CHERRY HILL DR CITY: DANVERS STATE: MA ZIP: 01923 BUSINESS PHONE: 9787775410 MAIL ADDRESS: STREET 1: 22 CHERRY HILL DRIVE CITY: DANVERS STATE: MA ZIP: 01923 4 1 form4-05312022_020509.xml X0306 4 2022-05-26 0000815094 ABIOMED INC NASD 0001372715 Greenfield Andrew J C/O ABIOMED, INC. 22 CHERRY HILL DRIVE DANVERS MA 01923 false true false false VP, CHIEF COMMERCIAL OFFICER Common Stock, $.01 par value 2022-05-26 4 A 0 5348 0 A 48291 D Common Stock, $.01 par value 2022-05-29 4 A 0 2150 0 A 50441 D Common Stock, $.01 par value 2022-05-29 4 F 0 954 266.34 D 49487 D Common Stock, $.01 par value 2022-05-29 4 F 0 366 266.34 D 49121 D Common Stock, $.01 par value 12032 I By Trust Stock Option (right to buy) 99.62 2017-05-24 2026-05-24 Common Stock 0 5000 D Stock Option (right to buy) 134.51 2018-05-15 2027-05-15 Common Stock 0 6500 D Stock Option (right to buy) 381.97 2019-05-16 2028-05-16 Common Stock 0 4000 D Stock Option (right to buy) 266.39 2020-05-30 2029-05-30 Common Stock 0 7000 D Stock Option (right to buy) 223.9 2021-05-29 2030-05-29 Common Stock 0 4896 D Stock Option (right to buy) 283.88 2022-05-25 2031-05-25 Common Stock 0 2868 D Consists of restricted stock units granted to the reporting person. One third of the restricted stock units will vest and the underlying shares will be issued to the reporting person on each of May 26, 2023, May 26, 2024 and May 26, 2025, so long as the reporting person continues to be employed by the issuer on the vesting dates. Represents shares of common stock underlying performance-based awards of restricted stock units granted to this reporting person on May 29, 2020. One hundred percent of these restricted stock units vested on May 29, 2022 (into an equal number of shares of common stock) based on the issuer's achievement of a certain performance milestone. Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2015 Omnibus Incentive Plan. These options become exercisable in annual 33-1/3% increments, commencing on the date shown in Table II, Column 6. /s/ Marc A. Began (by power of attorney) 2022-05-31 EX-24 2 ex24-05312022_020511.htm ex24-05312022_020511.htm

Limited Power of Attorney

The undersigned does hereby appoint each of Todd A. Trapp, Marc A. Began and Michael Dube, signing singly, the undersigned's true and lawful attorney-in-fact to:

(1) execute for and on behalf of the undersigned, in the undersigned's capacity as a director or officer of ABIOMED, Inc. (the "Company"), Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;

(2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5 and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and

(3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, this power of attorney has been executed as of the 30th day of June 2021 and shall remain in full force and effect until withdrawn by the undersigned in writing.

Signature: /s/ Andrew J. Greenfield

Print Name: Andrew J. Greenfield